Drugs / Breast milk
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT06746532 | Feb 2025 → Jan 2028 expected | brain hypoxia - ischemia, perinatal asphyxia | Semmelweis University | Recruiting | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT07661992 | Jul → Dec 2026 expected | — | Wake Forest University Health Sciences | Not yet recruiting | No outcome recorded |
| Phase not applicable3 trials · 1 met primary | ||||||
| — | NCT04883931 | May → Nov 2021 | retinopathy of prematurity | Baskent University | Completed | No outcome recorded |
| — | NCT04259320 | Feb → Jun 2020 | — | Karabuk University | Completed | Met primary |
| — | NCT03633500 | Aug → Dec 2018 | neonatal sepsis | Al Adan Hospital Kuwait | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2026-01-15 | Vaxart | Results Vaxart Publishes Positive Data for its Oral Bivalent Norovirus Candidate in Lactating Women and Their Infants vaxart.com ↗
the newly published study additionally shows vaccine-induced functional norovirus-specific antibodies in breastmilk and serum from vaccinated women, and norovirus-specific IgA in the stool of their breastfed infants. |
| 2025-01-27 | Supernus Pharmaceuticals, Inc. | Results Supernus Announces Label Update for Non-Stimulant ADHD Treatment, Qelbree®, Including New Pharmacodynamic Data and Information for Breastfeeding Women supernus.com ↗
These data support that the transfer of viloxazine into breastmilk is low. |
| 2024-04-30 | Vaxart | Results Vaxart Announces Positive Results for Its Bivalent Norovirus Vaccine Candidate in Lactating Mothers vaxart.com ↗
Breastmilk VP1-specific IgA rose on average 4.0 fold in response to G1.1 and 6.0 fold in response to GII.4 in the high dose group. |
All press releases naming this drug 6 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Breast milk | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04259320 ↗ |
| Modality | Other / unclassified | “Breast milk is a complex biological substance” NCT06746532 ↗ |
| Route | Oral | “Effectiveness of Mother's Own Colostrum and Breast Milk as Oral Immunotherapy” NCT03633500 ↗ |